Pharmaceuticals
November 7, 2023
Courtney M Vecera, Alan C. Courtes, Gregory Jones et al.
Treatment-resistant depression (TRD) is a term used to describe a particular type of major depressive disorder (MDD). There is no consensus about what defines TRD, with various studies describing between 1 and 4 failures of antidepressant therapies, with or without electroconvulsive therapy (ECT). That is why TRD is such a growing concern among clinicians and researchers, and it explains the...
European Archives of Psychiatry and Clinical Neuroscience
November 7, 2023
Ana-Maria Iorgu, Andrei-Nicolae Vasilescu, Natascha Pfeiffer et al.
2 citations
Abstract S-ketamine, a N-methyl-D-aspartate receptor (NMDAR) antagonist, and psilocybin, a 5-hydroxy-tryptamine (serotonin) 2A receptor (5-HT 2A R) agonist, are reported as effective rapid-acting antidepressants. Both compounds increase glutamate signalling and evoke cortical hyperexcitation. S-ketamine induces neurotoxicity especially in the retrosplenial cortex (Olney’s lesions). Whether...
Addiction
November 2, 2023
Celia J. A. Morgan
1 citation
Given the shifting public perception of psilocybin and associated legal changes, the increase in use observed by Keyes and Patrick is not surprising. The conclusion that this is a rising health concern is not justified by the data, particularly as in this sample non-lysergic acid diethylamide hallucinogen use seems to have increased in a white, educated, relatively higher socio-economic status...
American Journal on Addictions
November 1, 2023
Amanda Kim, Joji Suzuki
15 citations
In recent years, there has been accelerating scientific and public interest in the use of psychedelics to treat mental health disorders. Our study's objective was to assess the attitudes of addiction specialists regarding therapeutic psychedelics. Our study utilized an anonymous online survey to assess the opinions of 145 addiction specialists regarding the therapeutic promise, potential risks,...
bioRxiv : the preprint server for biology
October 31, 2023
Charlotte Maschke, Jordan O'Byrne, Michele Angelo Colombo et al.
7 citations
preprint
Consciousness has been proposed to be supported by electrophysiological patterns poised at criticality, a dynamical regime which exhibits adaptive computational properties, maximally complex patterns and divergent sensitivity to perturbation. Here, we investigated dynamical properties of the resting-state electroencephalogram of healthy subjects undergoing general anesthesia with propofol,...
Psychopharmacology
October 23, 2023
Sarah K. Danböck, Or Duek, Ziv Ben-Zion et al.
6 citations
Abstract: Rationale: A subanesthetic dose of ketamine, a non-competitive N-methyl-D-aspartate glutamate receptor (NMDAR) antagonist, elicits dissociation in individuals with posttraumatic stress disorder (PTSD), who also often suffer from chronic dissociative symptoms in daily life. These debilitating symptoms have not only been linked to worse PTSD trajectories, but also to increased...
European Psychiatry
October 23, 2023
I. B. Nita, O. D. Ilie, A. S. Ciobica et al.
Introduction Zebrafish (Danio rerio) has evolved over the years as a preferred organism due to its vast repertoire in research fields that mimic a targeted phenotype, particularly behavioral typologies and specific attributes comparable to murine models and relatively high homology with humans. Considering this consideration, different pharmacological treatments have been tested and proven that...
iScience
October 20, 2023
Jie-Ying Chen, Ke Wu, Miao-Miao Guo et al.
Depression is a global disease with a high prevalence. Here, we examine the role of the circuit from prelimbic mPFC (PrL) to the anterior ventral bed nucleus of the stria terminalis (avBNST) in depression-like mice through behavioral tests, immunofluorescence, chemogenetics, optogenetics, pharmacology, and fiber photometry. Mice exposed to chronic restraint stress with individual housing...
Frontiers in Psychiatry
October 19, 2023
Brian S. Barnett, Anahita Bassir Nia, Nathan Sackett et al.
1 citation
Disclosures of Financial or Other Potential Conflicts of Interest: Dr. Barnett holds stock options in CB Therapeutics. He also serves on advisory boards for CB Therapeutics and Compass Pathways. He receives monetary compensation from DynaMed Plus (EBSCO Industries, Inc.) for editorial work and from Janssen Pharmaceuticals for consulting services. Dr. Barnett has received research funding from...
European Eating Disorders Review
October 12, 2023
Johanna Louise Keeler, Carol Kan, Janet Treasure et al.
36 citations
Abstract Objective Treatment for anorexia nervosa (AN) remains challenging; there are no approved psychopharmacological interventions and psychotherapeutic strategies have variable efficacy. The investigation of evidence‐based treatments has so far been compounded by an underdeveloped understanding into the neurobiological changes associated with the acute stages of AN. There is converging...